Leerink Partnrs Brokers Raise Earnings Estimates for BOLT

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Investment analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Bolt Biotherapeutics in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings of ($0.34) per share for the quarter, up from their prior forecast of ($0.41). The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.23) EPS.

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus lowered their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Tuesday. Five analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and an average price target of $1.13.

Bolt Biotherapeutics Stock Down 0.1 %

Bolt Biotherapeutics stock opened at $0.44 on Friday. The business has a fifty day moving average price of $0.47 and a 200-day moving average price of $0.55. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56. The stock has a market capitalization of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $25,000. Squarepoint Ops LLC purchased a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth about $26,000. Velan Capital Investment Management LP acquired a new stake in Bolt Biotherapeutics in the fourth quarter valued at approximately $27,000. Citadel Advisors LLC acquired a new position in Bolt Biotherapeutics during the fourth quarter worth $42,000. Finally, FMR LLC lifted its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.